PDF(Pubmed)
Abstract：
UNASSIGNED: Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone marrow remains unclear.
UNASSIGNED: We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium-223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression-free survival for 17 months after the initial diagnosis.
UNASSIGNED: These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow.
UNASSIGNED: We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium-223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression-free survival for 17 months after the initial diagnosis.
UNASSIGNED: These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow.
摘要：
■前列腺癌中的骨髓播散性癌病很少见，预后不良。尽管强有力的证据表明，新型激素药物可改善转移性前列腺癌的预后，其在骨髓播散性癌中的有效性尚不清楚.
■我们在初步诊断时遇到了两例前列腺癌伴骨髓播散性癌。一名患者接受恩扎鲁他胺治疗,阿比特龙,多西他赛,卡巴他赛,denosumab,和镭-223，并在最初诊断后38个月死亡。另一名患者接受了阿帕鲁胺和地诺舒马的治疗，初始诊断后17个月无进展生存期.
■这些结果表明，即使在骨髓播散性癌病患者中，新型激素药物也可以改善前列腺癌的预后。
■我们在初步诊断时遇到了两例前列腺癌伴骨髓播散性癌。一名患者接受恩扎鲁他胺治疗,阿比特龙,多西他赛,卡巴他赛,denosumab,和镭-223，并在最初诊断后38个月死亡。另一名患者接受了阿帕鲁胺和地诺舒马的治疗，初始诊断后17个月无进展生存期.
■这些结果表明，即使在骨髓播散性癌病患者中，新型激素药物也可以改善前列腺癌的预后。
